openPR Logo
Press release

FERTINATAL™ DHEA Supplement for Diminished Ovarian Reserve Hits the Market

04-16-2012 09:22 PM CET | Health & Medicine

Press release from: Fertility Nutraceuticals, LLC

FERTINATAL™ DHEA Supplement for Diminished Ovarian Reserve

(New York, NY) – FERTINATAL™, the first and only dehydroepiandrosterone (DHEA) nutritional supplement designed to enhance female fertility, has entered the market today.

The launch took longer than expected, because Fertility Nutraceuticals, LLC - which developed the supplement - made unusual efforts to ensure that FERTINATAL™ DHEA for women would fulfill all of the required specifications which the product was designed for, with consistency across every tablet, according to Fertility Nutraceuticals. The required repeat rounds of quality-assurance testing at independent laboratories delayed the launch, initially scheduled for January.

“It was extremely frustrating, especially since we have seen increasing demand since we announced FERTINATAL last December,” notes Yu Kizawa, the company’s Director of Marketing and Sales. “Now, we are excited to be able to offer probably the most reliable micronized DHEA product on the market, and the only one specifically designed for women who have a difficult time conceiving.”

FERTINATAL™ was developed with strict adherence to the specifications of the Center for Human Reproduction (CHR, http://www.centerforhumanreprod.com), a research-driven fertility center in New York City that introduced DHEA supplementation for women with diminished ovarian reserve. Because of the high quality standard of FERTINATAL™, CHR, the only holder of female fertility-related U.S. patents for DHEA supplementation, endorses FERTINATAL™.

“Over-the-counter DHEA products can be very inconsistent in quality, even within the same brand,” explains Norbert Gleicher, MD, medical director of CHR. “Based on the unique quality control process of FERTINATAL™, we are confident that this new product will deliver the kind of consistency and quality we, up to this point, have been able to achieve only through pharmacy-compounded DHEA by prescription. We, therefore, feel confident in endorsing FERTINATAL™.”

FERTINATAL™ is available for purchase at $69.50 per box (a one-month supply), online at http://www.fertinatal.com.

About Fertility Nutraceuticals, LLC
Fertiltiy Nutraceuticals, LLC, is a company specializing in nutritional supplements for women in reproductive years. The company is dedicated to developing highest-quality nutritional supplements for women with fertility problems, trying to achieve healthy pregnancies. FERTINATAL™ is the company’s first product, with additional products planned for rollout throughout 2012.

Director of Marketing and Sales
Fertility Nutraceuticals, LLC
212-628-0851
info@fertinatal.com
http://www.fertinatal.com/
Fertility Nutraceuticals, LLC
1015 Madison Avenue #504
New York, NY 10075
USA

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release FERTINATAL™ DHEA Supplement for Diminished Ovarian Reserve Hits the Market here

News-ID: 218018 • Views:

More Releases from Fertility Nutraceuticals, LLC

Fertility Nutraceuticals, LLC Launches FERTINATAL Micronized DHEA Supplement for Enhanced Female Fertility
Fertility Nutraceuticals, LLC Launches FERTINATAL Micronized DHEA Supplement for …
Fertility Nutraceuticals, LLC – a company specializing in nutritional supplements for women and female fertility enhancement – is announcing the launch of FERTINATAL™ micronized dehydroepiandrosterone (DHEA) supplement. The high-quality DHEA supplement is designed to augment female fertility. Intrigued by anecdotal evidence received from one of their patients, physicians at New York’s Center for Human Reproduction (CHR) – a leading fertility and research center – initiated research on the relationship between

More Releases for FERTINATAL

Fertility Supplements Market Surges Amid Rising Demand for Reproductive Health S …
The Global Fertility Supplements Market size was valued at USD 1,977.30 million in 2021 and is estimated to grow at a CAGR of 9.60% over the forecast period 2024-2031. The Fertility Supplements Market, as analyzed by DataM Intelligence, offers a comprehensive industry overview backed by in-depth insights, historical trends, and key statistics. The report dives deep into market dynamics and competitive strategies, profiling major players along with their product portfolios, pricing
Fertility Supplements Market Research Report: Growth Insights and Key Players (2 …
DataM Intelligence has released a new research report on the Fertility Supplements market. The report provides a detailed analysis of current and emerging trends, offering insights into the market dynamics. It utilizes Porter's Five Forces model to assess key factors such as supplier and customer relationships, risks from various agents, competitive intensity, and opportunities for new entrants. The study also includes research data from various companies, analyzing factors like benefits,
The Prenatal Vitamin Supplements market is expected to reach at USD 1,040.23 Mil …
Market Overviews: Prenatal vitamins are supplements designed to provide pregnant women with the vitamins and minerals they require for a healthy pregnancy. Prenatal vitamins can be purchased over the counter at almost any drugstore. They assist in the development of the baby's teeth and bones. It could also be good to seek for a prenatal vitamin that has vitamins C, A, E, B vitamins, zinc, and iodine. Summary: The prenatal vitamin supplements market
Fertility Nutraceuticals, LLC Launches FERTINATAL Micronized DHEA Supplement for …
Fertility Nutraceuticals, LLC – a company specializing in nutritional supplements for women and female fertility enhancement – is announcing the launch of FERTINATAL™ micronized dehydroepiandrosterone (DHEA) supplement. The high-quality DHEA supplement is designed to augment female fertility. Intrigued by anecdotal evidence received from one of their patients, physicians at New York’s Center for Human Reproduction (CHR) – a leading fertility and research center – initiated research on the relationship between